The Food and Drug Administration has appointed Ross Segan, a former executive in the device industry and Army veteran, to lead its division responsible for ensuring the safety of medical devices.
Prior to joining the FDA, Segan served as the chief medical officer at Olympus from 2020 to 2023. Olympus is a prominent distributor of endoscopes and was at the center of controversy when the FDA issued warning letters citing the company’s failure to adequately address product defects. One such issue involved instances where endoscope caps fell into patients’ bodies, raising serious concerns about patient safety.
Jeffrey Shuren, the head of FDA’s medical devices center, expressed deep concern over Olympus’ repeated failure to meet FDA requirements, emphasizing the company’s disregard for patient safety.
Segan’s background in the device industry and his experience at Olympus provide him with valuable insights into the challenges and complexities of ensuring medical device safety. His leadership will be instrumental in addressing regulatory compliance issues and enhancing safety standards within the medical device industry.
As the new head of the FDA division overseeing medical device safety, Segan is expected to prioritize patient safety and work closely with industry stakeholders to uphold the highest standards of quality and safety in medical device manufacturing and distribution.
This appointment underscores the FDA’s commitment to safeguarding public health and underscores the importance of robust regulatory oversight in the medical device sector. Segan’s leadership will play a crucial role in advancing the FDA’s mission of protecting and promoting the health of the American public.
In conclusion, Ross Segan’s appointment as the head of the FDA division responsible for medical device safety represents a significant step towards strengthening regulatory oversight and ensuring the safety and effectiveness of medical devices in the healthcare industry.
